Two forms of lactoferrin, an intact lactoferrin and a "nicked" but apparently intact (i.e., 78-kDa) form, have been isolated from the urine of preterm infants fed human milk. These two forms of lactoferrin, demonstrated to be entirely of maternal origin, were copurified using affinity columns of immobilized single-stranded DNA-agarose. The relative concentrations of the intact lactoferrin and the "nicked" lactoferrin were determined after denaturation and separation by reverse-phase HPLC. N-terminal sequence analyses showed that the Intact 78-kDa form had lost two residues from its N terminus. The nicked 78-kDa form was composed of only two fragments; one fragment was identified as the N terminus of the N-lobe (residues 3-283). The other fragment started with Ser-284 and included the a-helical structures at the C terminus of the N-lobe, as well as the entire C-lobe. Although no disulfide bonds connect these two fragments, they were tightly associated in vivo and were not separated in vitro except under denaturing conditions. Limited in vitro digestion of human milk lactoferrin with trypsin produced a nicked, but stable (78-kDa), form of DNA-binding lactoferrin nearly indistinguishable from the isolated urinary lactoferrin, except for the absence of one additional arginine residue at the N terminus of the N-lobe. Residues involved in the stable molecular interaction between fragments were evaluated using data obtained from the high-resolution crystal structure of hololactoferrin. Two features, entirely within the N-lobe, account for the lack of fragment dissociation after cleavage at residue 283 in vivo: an extensive interface at the hinge region behind the ironbinding cleft and an "anchor" sequence traversing the remainder ofthe N-lobe at 90' relative to the fragment interface. These results document the remarkably limited degradation of absorbed lactoferrin in vivo and suggest that iron-binding activity, receptor-binding properties, and postulated immune cell regulatory functions remain intact.
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Lactoferrin is a 78-kDa metal-binding protein found in milk and various other mucosal secretions (1) . It is also a component of neutrophil secretory granules and is generally thought to be important in host defense (1, 2) . It has been associated with the promotion of cell growth (e.g., refs. 3 and 4), regulation of hematopoiesis, and immune-modulating properties (e.g., refs. 5-8) in vitro. Little, however, is known about the function and metabolism of lactoferrin in vivo.
Lactoferrin is the major protein component of human colostral whey (9) and has been a focus of attention in numerous investigations of the nutrition and host defense of term and preterm infants (10) (11) (12) (13) (14) (15) (16) (17) . Since human lactoferrin has been cloned (18) , overexpression and large-scale production are imminent. Thus, an increased need for the characterization of lactoferrin structure, function, and metabolism in vitro is anticipated. We have reported the identification and purification of intact (78-kDa) lactoferrin from the urine of preterm infants fed human milk (19) . We (20) . In addition to identifying intact lactoferrin in urine from these infants, we found two major lactoferrin fragments and demonstrated both to be of maternal origin (20) .
We have now identified the proteolytic cleavage site acted upon in vivo during the generation of the 78-kDa "nicked" form of lactoferrin, and we present biochemical evidence to suggest that resulting "fragments" remain tightly associated both in vivo and in vitro as a result of extensive noncovalent interactions. Since the high-resolution structure of human lactoferrin has been described (21, 22) , the nature of the contact points responsible for this high-affinity fragment association is discussed. The potential developmental and therapeutic implications of these findings are also presented.
MATERIALS AND METHODS
Purification and Characterization of Urinary Lactoferrin. The urine of very low birth weight (0.86-1.20 kg) infants who had received only fortified human milk (19, 20) was pooled and stored at -700C. Urinary lactoferrin was purified to homogeneity by affinity chromatography on single-stranded DNA (ssDNA)-agarose (19, 20 (20) . Sodium dodecyl sulfate/polyacrylamide gradient gel electrophoresis (SDS/PAGGE) was performed using the buffer system of Laemmli (21) , and gels were silver-stained (22) . Western transfer and immunoblotting with polyclonal anti-human lactoferrin antibodies (nonreducing gels) were done as described (23) .
Trypsin Digestion of Human Milk Lactoferrin. Purified human milk lactoferrin (10 mg/ml) was subjected to mild trypsin digestion (23 Amino Acid Sequence Analyses. The N-terminal amino acid sequences of milk and urinary lactoferrin forms (intact and fragments) were determined by sequential Edman degradation (24) using an automated pulsed liquid sequenator (model 473A, Applied Biosystems). Samples were analyzed at least in duplicate; repetitive yields were >90%o.
Lactoferrin Structure. Lactoferrin structures were evaluated using the program FRODO (25) on a VAX 8810 computer equipped with an Evans and Sutherland PS390 molecular graphics terminal. The refined coordinates for human lactoferrin (26, 27) were generously provided by Edward N. Baker and colleagues (Massey University, New Zealand).
RESULTS
The urinary lactoferrin used was exclusively of maternal origin (20) ; it was purified by ssDNA-affinity chromatography from 30 different pools of urine (0. 1-225 ,.g of lactoferrin per ml) collected only from preterm infants fed human milk. Characterization of the purified urinary lactoferrin by sizeexclusion HPLC suggested the presence of only intact (78-kDa) lactoferrin, indistinguishable in hydrodynamic properties from purified human milk lactoferrin ( Fig. 1 , top three profiles).
When the purified urinary lactoferrin was fully denatured and evaluated by SDS/PAGGE, two large fragments, in addition to intact (78-kDa) lactoferrin, were revealed. Fig. 2A shows a typical (n = 14) electrophoretic pattern for lactoferrin purified by DNA-affinity chromatography from infant urine; when denatured and reduced, only three major pro- Size-exclusion HPLC of purified human milk lactoferrin (top profile), purified urinary lactoferrin (second profile), and trypsin-digested human milk lactoferrin (third profile). The elution positions of the intact urinary lactoferrin (peak 3) and urinary lactoferrin fragments (peaks 1 and 2) after their separation and resolution by reverse-phase chromatography (see Fig. 3 ) are shown for reference. The numbers correspond to the reverse-phase peak numbers shown in Fig. 3 2 . SDS/10-20% PAGGE and immunoblot analysis of lactoferrin forms isolated by affinity chromatography on ssDNAagarose. The affinity-purified urinary lactoferrin forms were compared with human milk lactoferrin fragments generated by limited trypsin digestion in vitro. All samples in A were analyzed under denaturing and reducing conditions. Protein bands in A (all lanes) and lanes 1 and 2 of B were visualized by silver staining. (A) Lanes: 1, calibrator proteins for estimation of molecular mass; 2, commercially obtained lactoferrin (Jackson Immunoresearch); 3, intact human milk lactoferrin isolated by DNA-affinity chromatography; 4, urinary lactoferrin (intact form and associated lactoferrin fragments) isolated by DNA-affinity chromatography; 5, human milk lactoferrin forms after limited trypsin digestion in vitro. (B) Urinary lactoferrin samples in lanes 2 and 3 were prepared and electrophoresed in the absence of reducing agent. Lanes: 1, calibrator proteins; 2, urinary lactoferrin (intact form and associated lactoferrin fragments) isolated by DNA-afflinity chromatography; 3, immunoblot analysis of the urinary lactoferrin forms shown in lane 2.
teins were revealed by silver staining. The protein in each of the three bands (present in both the presence and the absence of reducing agent) was identified as lactoferrin by immunoblotting with anti-human lactoferrin antibodies (Fig. 2B) . No major protein bands below 39 kDa were detected.
The intact (78-kDa) forms of lactoferrin and the two lactoferrin fragments revealed under denaturing conditions by SDS/PAGGE were not separated by immobilized metal ion affinity or size-exclusion (TSK-3000SW) HPLC in buffers with up to 6 M urea or 6 M guanidine hydrochloride. Similarly, they were not resolved by ion-exchange (Mono S) HPLC, even in buffers with 6 M urea or up to 1% Triton X-100 (data not shown). An efficient (i.e., high-resolution) and preparative separation of the intact urinary lactoferrin from the 51-kDa and 39-kDa fragments was finally achieved by reverse-phase HPLC on Vydac phenyl-derivatized silica gel columns, with heptafluorobutyric acid as an ion-pairing reagent. The elution profiles in Fig. 3A illustrate the typical (n = 30) variations observed for the urinary lactoferrin purified by DNA-affinity chromatography. The major reverse-phase peaks 1-3 were identified separately by SDS/PAGGE and N-terminal sequence analyses (Table 1) . Peaks 1 and 2 were identified as the 39-kDa N-terminal lobe fragment (residues 3-283) and the 51-kDa fragment containing some of the N-lobe (beginning at residue 284) and the entire C-terminal lobe. Peak 3 was identified as intact (78-kDa) urinary lactoferrin; only the first two residues (Gly-Arg) were missing.
Only after structural dissociation of the 78-kDa nicked lactoferrin in vitro, and separation of the urinary lactoferrin fragments by reverse-phase chromatography, were. these fragments fully resolved from each other and separated from the intact 78-kDa form of lactoferrin by size-exclusion chromatography as described in Fig. 1 (see bottom two profiles) .
The in vivo association of urinary lactoferrin fragments 1 and 2 was further suggested by integration of the individual reverse-phase peak areas in Fig. 3 . The urinary lactoferrin fragments 1 and 2 generally appeared in constant relative ratios. The mean ratio of peak 1 to peak 2 was 1.13 ± 0.11 (n = 30) within a narrow total range of 0.76-1.25. The ratio of the 78-kDa nicked form to intact lactoferrin was estimated by comparing the quantity of protein in peaks 1 and 2 (derived from the nicked 78-kDa form) to the quantity of protein in peak 3 (intact 78-kDa form). The mean ratio of peaks 1 plus 2 to peak 3 was 1.46 ± 1.09 (n = 30); the range, however, was quite variable (0.29-3.92).
The results obtained with the purified urinary lactoferrin were duplicated by the in vitro manipulation of human milk lactoferrin. Fig. 3B shows the reverse-phase HPLC profiles of human milk lactoferrin after 0-21 hr of trypsin digestion in vitro, before and after affinity chromatography on ssDNAagarose. Fig. 3C shows that the elution profile of trypsindigested (21 hr) human milk lactoferrin was not influenced by previous affinity chromatography on ssDNA-agarose. We observed a gradual variation in the ratio of peaks 1 plus 2 to peak 3 with time of trypsin digestion; intact milk lactoferrin (peak 3) was decreased by 60% during the 21-hr digestion.
The N-terminal sequence data shown in Table 1 identify the one interior or "major" (after Lys-283) and one exterior or "minor" (after Arg-2) proteolytic cleavage points in the isolated urinary lactoferrin. Both the 78-kDa urinary lactoferrin (reverse-phase peak 3) and the 39-kDa N-terminal lobe fragment (peak 1) were missing the first two amino acid residues (Gly-Arg). The major proteolytic cleavage point in the 78-kDa urinary lactoferrin occurred at Lys-283 during both limited and prolonged trypsin digestion in vitro. An additional residue, Arg-3, was missing in the 78-kDa intact lactoferrin and N-lobe fragment that was generated by trypsin digestion in vitro.
The peptide backbone structure of human hololactoferrin as derived from the x-ray structure data of Anderson et al. (26) is shown in Fig. 4 . The sequence numbering has been modified by the addition of one additional arginine residue to reflect the N-terminal amino acid sequence data for human milk lactoferrin determined by us (Table 1) and by others (28) . The crystal structure sequence numbering in the N terminus is therefore modified accordingly (+1) relative to that of Metz-Boutigue et al. (28) beginning at Ser-6. The corrected sequence, containing four arginines (residues 2-5), has been confirmed by the cDNA sequence for human lactoferrin (18) . The molecular lactoferrin structure shown in Fig. 4 has been modified to reflect our results with the purified urinary lactoferrin. That is, the N-terminal Gly-Arg has been removed; the sequence shown begins at Arg-3. The peptide bond between Lys-283 and Ser-284 [by our modified Anderson (26) numbering and by the Powell and Ogden (18) (Table 1 ). The N-lobe (residues 3-340) and C-lobe (residues 341-691) portions of the molecule are identified; an arrow (top center) marks the point in the primary sequence (residue 340) between the two homologous lobes. The cleavage site between Lys-283 and Ser-284 is also shown by an arrow (lower left). The tightly associated 39-kDa portion (residues 3-283; blue) and 51-kDa portion (residues 284-691; yellow) of the nicked urinary lactoferrin are illustrated to highlight the interface region. An arrow at residue 312 (bottom center) shows the point at which the anchor sequence (residues 312-284) departs to the left (at 90°) away from the a-helical interface. Bound ferric ions in the N-lobe and C-lobe are identified in red.
sequence numbering] has been broken to reflect the known trypsin-like proteolytic cleavage. That portion of the N-lobe sequence shown in blue (residues 3-283) is identified as urinary lactoferrin fragment 1. The remaining N-lobe to C-lobe portion (residues 284-691) shown in yellow is identified as urinary lactoferrin fragment 2. The N-terminal cleavage site between Arg-2 and Arg-3 (bottom, blue region of N-lobe) is seen to be readily accessible in the region between the N-lobe and C-lobe. The second, major N-lobe cleavage site identified in the purified urinary lactoferrin, and in the human milk lactoferrin digested with trypsin in vitro, is at the lower entrance to the N-lobe iron-binding cleft at Lys-283. The two fragments appear to be associated at an extensive interface within the N-lobe, clearly defined by the repeating a-helical structures in the C-terminal region of the N-lobe (residues 313-335, yellow) and the hinge region behind the iron-binding cleft (blue). A nonhelical "anchor" sequence (residues 312-284, yellow) extends to the left from Pro-312 back through the residual N-lobe structure (blue) at a right angle to the fragment interface.
DISCUSSION
Two large (78-kDa) and nearly indistinguishable forms of maternal lactoferrin were demonstrated in the urine of preterm infants fed human milk. Some of the urinary lactoferrin had resisted almost entirely the proteolysis and degradation typically associated with digestion, absorption, transport, and excretion; the remainder of the isolated urinary lactoferrin appeared to retain an intact tertiary structure despite a nick deep within the primary sequence.
The constant relative ratio (1:1) of urinary lactoferrin fragments 1 and 2 observed after their denaturation and separation in vitro (by reverse-phase chromatography) suggested that these two fragments were never dissociated as a result of proteolytic digestion in vivo. This conclusion is supported by results from several types of nondenaturing chromatography. Neither form of urinary lactoferrin identified had lost its affinity for DNA, yet the fragments separated by reverse-phase chromatography had no affinity for anionic structures evaluated to date (e.g., Mono S). Despite the demonstrated ability of metal ion interaction HPLC to resolve closely related proteins of the transferrin gene family (29) , apo and holo forms of lactoferrin (29, 30) , and peptides (31) and proteolytic degradation products (32) , there was no indication of urinary lactoferrin degradation or heterogeneity; the purified urinary lactoferrin was coeluted with human milk hololactoferrin from columns of immobilized Cu(II) ions (data not shown).
Thus, we conclude that two major forms of urinary lactoferrin exist. Both forms, although equivalent in mass (78 kDa), are missing the first two residues. Except for these two residues, each 78-kDa form of urinary lactoferrin appeared structurally and functionally intact; one form, however, is nicked at residue 283 in the N1 domain. Our present inability to distinguish (or separate) the two 78-kDa forms of urinary lactoferrin by biochemical means, except under denaturing conditions, hinders our ability to determine whether the proteolytic nick at residue 283 alters tertiary structure.
Evaluation of lactoferrin tertiary structure shows that the cleavage site at residue 283 neither defines nor separates the N-lobe and C-lobe domains (the C-lobe begins at residue 341). Furthermore, there are no disulfide bonds between these two portions of the intact molecule (or between the intact N-lobe and C-lobe). What structural features account for the high-affinity association of these two fragments both in vivo and in vitro? A clear and extensive interface between fragment 1 (blue) and fragment 2 (yellow) is defined by residues 313-335 (Fig. 4) . It runs the entire vertical axis ofthe N-lobe. This portion of the N-lobe, opposite the iron-binding cleft, defines helix 11 at the interface between the N1 and N2 N-lobe domains. In addition, residues 312 back through 284 create an anchor in the remaining N-lobe structure; this sequence defines the upper portion of the N1 domain at the entrance to the iron-binding cleft. That portion of the molecule in the region of the cleavage site, the N1 domain, is a relatively stable structure and is apparently similar in both the apo and holo forms of the molecule. Iron binding causes N-lobe 3 C-lobe only the upper domain (N2) of the N-lobe to rotate (530) closed; the lower N1 domain shows relatively little change in structure upon iron binding (26, 27) . Opening of the N-lobe iron-binding cleft exposes only three basic residues, Arg-121, Arg-211, and Lys-302; although apolactoferrin is thought to be more sensitive to proteolytic attack (1), there is no evidence that these residues are attacked by trypsin or trypsin-like enzymes in vivo, either in the apoprotein or in the holoprotein.
Our finding of intact (78-kDa) maternal lactoferrin forms in the urine of preterm infants suggests that this protein is more than simply a source of amino acids. Indeed, maternal lactoferrin may also be more than a transient immunoprotective reagent localized exclusively to the gastrointestinal tract. The preserved structure and function of both urinary lactoferrin forms demand further consideration of several specific biological implications. Once maternal lactoferrin is absorbed, a process possibly mediated by specific receptors (33, 34) , it may retain enough of its original conformation to conserve specific lymphocyte-binding properties (e.g., ref. 35) . Lactoferrin may then act in its capacity to regulate the development and function of lymphocytes and other immune cells (1, (5) (6) (7) (8) . We have not examined the urine of term or "mature" breast-fed infants for the presence of intact lactoferrin or other intact proteins of maternal origin. The developmental biology of the gastrointestinal tract and renal tubular function in preterm infants is not well characterized. Thus, the mechanism (e.g., increased permeability or specific transport) of lactoferrin entry into the urinary tract of these infants is not known.
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